Eli Lilly has scrapped a drug being tested for use against Alzheimer’s disease because it increased patients’ symptoms and was also tied to a higher risk of skin cancer. As Dow Jones Newswires reports, the announcement — on top of the disappointing results for another experimental drug reported earlier this year by Pfizer and Medivation — underlines how hard it is to develop new treatments for Alzheimer’s.
But why is it so hard?
That’s the question we posed to P. Murali Dora